Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF MEDICAL OFFICER | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,115 |
Ending reported balance
After 2026-09-18 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 900 · Balance 14,015 Row 2 · 2026-09-16 · Exercise / conversion · Acquired 900 · Balance 14,915 Row 3 · 2026-09-16 · Sale · Disposed 1,800 · Balance 13,115 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-09-17 · Exercise / conversion · Acquired 400 · Balance 13,515 Row 5 · 2026-09-17 · Exercise / conversion · Acquired 400 · Balance 13,915 Row 6 · 2026-09-17 · Sale · Disposed 800 · Balance 13,115 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 7 · 2026-09-18 · Exercise / conversion · Acquired 10,406 · Balance 23,521 Row 8 · 2026-09-18 · Exercise / conversion · Acquired 25,446 · Balance 48,967 Row 9 · 2026-09-18 · Sale · Disposed 35,852 · Balance 13,115 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.69 · Expires 2034-01-24 | Direct | 29,400 |
Reported balance
After 2026-09-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-16 · Exercise / conversion · Disposed 900 · Balance 29,400 F4: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.27 · Expires 2034-05-01 | Direct | 63,346 |
Reported balance
After 2026-09-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-16 · Exercise / conversion · Disposed 900 · Balance 63,346 F5: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.69 · Expires 2034-01-24 | Direct | 29,000 |
Reported balance
After 2026-09-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-17 · Exercise / conversion · Disposed 400 · Balance 29,000 F4: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.27 · Expires 2034-05-01 | Direct | 62,946 |
Reported balance
After 2026-09-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-17 · Exercise / conversion · Disposed 400 · Balance 62,946 F5: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.69 · Expires 2034-01-24 | Direct | 18,594 |
Reported balance
After 2026-09-18 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-18 · Exercise / conversion · Disposed 10,406 · Balance 18,594 F4: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.27 · Expires 2034-05-01 | Direct | 37,500 |
Reported balance
After 2026-09-18 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-18 · Exercise / conversion · Disposed 25,446 · Balance 37,500 F5: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F5: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 25,446 | $0.00 Strike: $30.27 | $0.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · derivative · entry 15 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 25,446 shares Expires 2034-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 18, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,406 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · derivative · entry 14 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,594 Underlying: Common Stock · 10,406 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 18, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 35,852 | $43.05 | $1,543,589.93 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 9 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 25,446 | $30.27 | $770,250.42 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 8 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,406 | $30.69 | $319,360.14 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 7 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 400 | $0.00 Strike: $30.27 | $0.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · derivative · entry 13 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,946 Underlying: Common Stock · 400 shares Expires 2034-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 400 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · derivative · entry 12 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 400 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 800 | $43.00 | $34,400.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 6 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 400 | $30.27 | $12,108.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 5 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 400 | $30.69 | $12,276.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 4 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 900 | $0.00 Strike: $30.27 | $0.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · derivative · entry 11 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,346 Underlying: Common Stock · 900 shares Expires 2034-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 900 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · derivative · entry 10 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 900 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,800 | $43.01 | $77,426.28 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 3 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 900 | $30.27 | $27,243.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 900 | $30.69 | $27,621.00 |
DisclosureSEC source: 0002009762-26-000006 · form4-09182026_080908.xml · nonDerivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,754 | $0.00 Strike: $30.27 | $0.00 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · derivative · entry 8 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,246 Underlying: Common Stock · 10,754 shares Expires 2034-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 12,200 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · derivative · entry 7 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,300 Underlying: Common Stock · 12,200 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 22,954 | $43.10 | $989,349.54 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · nonDerivative · entry 6 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,754 | $30.27 | $325,523.58 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · nonDerivative · entry 5 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 12,200 | $30.69 | $374,418.00 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · nonDerivative · entry 4 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,000 | $42.79 | $42,794.70 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · nonDerivative · entry 3 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $43.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,500 | $42.25 | $190,113.75 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · nonDerivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,115 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.59 to $42.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 21:12 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,500 | $41.98 | $230,911.45 |
DisclosureSEC source: 0002009762-26-000005 · form4-09092026_090911.xml · nonDerivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,615 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.32. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 18, 2026 16:14 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000004 · form4-05182026_080508.xml · derivative · entry 3 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award of restricted stock units was previously granted on May 1, 2024 and shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.exercise_date: The award of restricted stock units was previously granted on May 1, 2024 and shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.expiration_date: The award of restricted stock units was previously granted on May 1, 2024 and shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F1 · balance_after: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock and derivatives beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing. Read SEC document |
| May 01, 2026 Filed May 18, 2026 16:14 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 8,882 | $31.83 | $282,714.06 |
DisclosureSEC source: 0002009762-26-000004 · form4-05182026_080508.xml · nonDerivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,115 F2 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| May 01, 2026 Filed May 18, 2026 16:14 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000004 · form4-05182026_080508.xml · nonDerivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock and derivatives beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,662 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · derivative · entry 8 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,988 Underlying: Common Stock · 2,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_price: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.expiration_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 1,372 | $36.82 | $50,517.04 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · nonDerivative · entry 4 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,290 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,662 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · nonDerivative · entry 3 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · derivative · entry 7 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,175 Underlying: Common Stock · 2,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 1,153 | $36.82 | $42,453.46 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · nonDerivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,035 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · nonDerivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · derivative · entry 6 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 42,600 | $0.00 Strike: $36.76 | $0.00 |
DisclosureSEC source: 0002009762-26-000002 · form4-01262026_090132.xml · derivative · entry 5 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,600 Underlying: Common Stock · 42,600 shares Expires 2036-01-22 F2 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| May 01, 2025 Filed May 9, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012477 · form4-05092025_080555.xml · derivative · entry 3 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The award of restricted stock units was previously granted on May 1, 2024 and shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The award of restricted stock units was previously granted on May 1, 2024 and shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The award of restricted stock units was previously granted on May 1, 2024 and shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| May 01, 2025 Filed May 9, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 8,869 | $29.86 | $264,828.34 |
DisclosureSEC source: 0001415889-25-012477 · form4-05092025_080555.xml · nonDerivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,881 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| May 01, 2025 Filed May 9, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012477 · form4-05092025_080555.xml · nonDerivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 16:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 10,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002161 · form4-01282025_090114.xml · derivative · entry 5 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,650 Underlying: Common Stock · 10,650 shares Expires not disclosed F4 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 16:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 37,400 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0001415889-25-002161 · form4-01282025_090114.xml · derivative · entry 4 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,400 Underlying: Common Stock · 37,400 shares Expires 2035-01-25 F3 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002161 · form4-01282025_090114.xml · derivative · entry 3 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,563 Underlying: Common Stock · 2,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 1,151 | $38.01 | $43,749.51 |
DisclosureSEC source: 0001415889-25-002161 · form4-01282025_090114.xml · nonDerivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,036 F1 · date: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002161 · form4-01282025_090114.xml · nonDerivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012110 · form4-05032024_080501.xml · derivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $30.27 | $0.00 |
DisclosureSEC source: 0001415889-24-012110 · form4-05032024_080501.xml · derivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-05-01 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:59 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001875 · form4-01262024_090148.xml · derivative · entry 2 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires not disclosed F2 · security: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:59 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 42,500 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0001415889-24-001875 · form4-01262024_090148.xml · derivative · entry 1 Budur Kumar · CIK 0002009762 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2034-01-24 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.